Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness

Sitting

10 July 2025

This vote

Vote 15 of 22 on this subject — a vote on part of the text

This part

‘underlines that the sector is characterised by high levels of risk and that reducing the cost of investment failure in the EU is necessary for attracting large-scale capital investment; calls for dedicated support to ensure that biotechnology and biomanufacturing SMEs, start-ups and scale-ups can access sufficient funding and compete globally; stresses that cross-border investment barriers must be reduced to facilitate investment in biotechnology and biomanufacturing scale-ups;’

Requested by

split vote: Members · roll call: Members

Amendments change the text; the final vote decides it.